New Guidelines for Platelet Transfusion Recommend Restrictive Strategies While RBC transfusions have declined with the widespread adoption of restrictive thresholds, platelet transfusions have remained steady in recent years…. May 29, 2025
New FDA Draft Guidance to Reduce Transfusion-Transmitted Malaria Malaria, caused by five Plasmodium species (e.g., P. falciparum), is recognized as a significant transfusion-transmitted infection by the U.S. Food… January 22, 2025
RBC Transfusions Guidelines for Very Preterm Infants Most clinical practice guidelines for blood transfusion have focused on adults and limited recommendations are available for children and neonates…. July 9, 2024
Ferritin-Guided Blood Donations Protect Iron Stores in Donors In both North America and Europe, whole blood donors are eligible to donate whole blood every 56 days. Donors lose… July 3, 2024
Donor Deferral Model Evaluates Impact of New Individual Risk Assessment When AIDS emerged in the early 1980s, the risk of acquiring HIV from a transfusion was approximately 1.1%. The U.S…. June 28, 2024
AABB Clinical Practice Guidelines for RBC Transfusions The AABB has updated their clinical practice guidelines regarding RBC transfusion thresholds. The guidelines are based on data from 45… October 12, 2023
FDA Guidance for COVID-19 Convalescent Plasma to Remain in Effect During the public health emergency for COVID-19, the U.S. Food and Drug Administration (FDA) issued guidance for the use of… March 22, 2023
New Draft FDA Guidance to Reduce the Risk of HIV Transfusion-Transmission Using Individual Risk-Based Questions The U.S. FDA recently issued draft guidance to reduce the risk of HIV transfusion-transmission using individual risk-based questions instead of… January 31, 2023
Updated FDA Guidance to Reduce the Risk of Transfusion-Transmitted Malaria In April 2020, the U.S. Food and Drug Administration (FDA) issued four blood donor eligibility guidelines—including one for malaria—to help… December 13, 2022
Donor Deferral Recommendations for HIV Pre-exposure Prophylaxis In December 2021, the U.S. FDA approved injectable cabotegravir (Apretude) as pre-exposure prophylaxis (PrEP) to prevent HIV transmission. PrEP, post-exposure… September 14, 2022
Policy and Guidelines